USPTO serial 99699133
PROGRAM CANCER AGAINST ITSELF
Reviewed by CopyMark Law Group
- Filing date
- Status date
- Registration date
- —
- Examiner
- LOBO, DEBORAH E
- Law office
- PUBLICATION AND ISSUE SECTION
What this means
Status 686 means your mark is published in the USPTO Official Gazette and in the 30-day opposition period. If no opposition is filed, prosecution typically continues toward registration or a Notice of Allowance. Monitor the opposition window. After it closes, watch for Notice of Allowance (intent-to-use) or registration (use-based).
Need help with PROGRAM CANCER AGAINST ITSELF?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Redwood City, CA, US
Redwood City, CA, US
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Ted D. Karr
Ted D. Karr Berkeley Law & Technology Group LLP7710 Rialto Blvd, Suite 100Austin, TX 78735United StatesGoods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 005 | Products for the prevention of cancer in humans, namely, pharmaceutical products to express a synthetic biomarker for detecting cancer; Products for the detection of cancer in humans, namely, pharmaceutical products to express a synthetic biomarker for detecting cancer; Products for the localization of cancer in humans, namely, pharmaceutical products to express a synthetic biomarker for localization of cancer; Products for the therapy of cancer in humans, namely, pharmaceutical products to express a treatment agent for treating cancer; Products for the prevention of cancer in animals, namely, pharmaceutical products to express a synthetic biomarker for detecting cancer; Products for the detection of cancer in animals, namely, pharmaceutical products to express a synthetic biomarker for detecting cancer; Products for the therapy of cancer in animals, namely, pharmaceutical products to express a treatment agent for treating cancer | ACTIVE | — |
| 044 | Medical services for the prevention of cancer in humans, namely, medical assay processing provided by medical laboratories and medical analysis services for detecting cancer; Medical services for the detection of cancer in humans, namely, medical assay processing provided by medical laboratories and medical analysis services for detection of cancer; Medical services for the localization of cancer in humans, namely, medical assay processing provided by medical laboratories and medical analysis services for the localization of cancer; Medical services for the therapy of cancer in humans, namely, medical assay processing provided by medical laboratories and medical analysis services for treating cancer; Medical services for the prevention of cancer in animals, namely, medical assay processing provided by medical laboratories and medical analysis services for detecting cancer; Medical services for the detection of cancer in animals, namely, medical assay processing provided by medical laboratories and medical analysis services for detection of cancer; Medical services for the therapy of cancer in animals, namely, medical assay processing provided by medical laboratories and medical analysis services for the treatment of cancer | ACTIVE | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Sep 15, 2026 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| Sep 15, 2026 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Sep 9, 2026 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| Aug 18, 2026 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Jun 28, 2026 | GNRN | NOTIFICATION OF NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Jun 28, 2026 | GNRT | NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Jun 28, 2026 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Jun 22, 2026 | DOCK | ASSIGNED TO EXAMINER | — |
| Mar 12, 2026 | MAFR | APPLICATION FILING RECEIPT MAILED | — |
| Mar 12, 2026 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Mar 12, 2026 | NWAP | NEW APPLICATION ENTERED | — |